Capital Asset Advisory Services’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Capital Asset Advisory Services’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-532	Closed	–	–	1666
2020 Q4	$0	Hold	532	–	–	﹤0.01%	1626
2020 Q3	$1K	Sell	532 -116	-18%	-$331	﹤0.01%	546
2020 Q2	$2K	Sell	648 -8	-1%	-$29	﹤0.01%	552
2020 Q1	$2K	Sell	656 -269	-29%	-$886	﹤0.01%	490
2019 Q4	$3K	Buy	+925	New	+$2.4K	﹤0.01%	562

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Capital Asset Advisory Services's BMY.RT Position: Q1 2021 in Review

Capital Asset Advisory Services sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 532 shares.

Capital Asset Advisory Services first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $3K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Capital Asset Advisory Services reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Capital Asset Advisory Services sold 532 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
Capital Asset Advisory Services first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Capital Asset Advisory Services's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3K in Q4 2019.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Capital Asset Advisory Services's 13F filing for Q1 2021, filed 13 May 2021.